Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

(2021) Hagop M. Kantarjian et al.   LEUKEMIA

Impact of frontline treatment approach on outcomes of myeloid blast phase CML

(2021) Kapil Saxena et al.   Journal of Hematology & Oncology

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

(2020) A. Hochhaus et al.   LEUKEMIA

Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias

(2020) Abhishek Maiti et al.   ACTA HAEMATOLOGICA

Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia

(2020) Yasmin Abaza et al.   AMERICAN JOURNAL OF HEMATOLOGY

Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party

(2019) Aleksandar Radujkovic et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Management of Chronic Myeloid Leukemia in Advanced Phase

(2019) Massimiliano Bonifacio et al.   Frontiers in Oncology

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial

(2018) Jorge E. Cortes et al.   BLOOD

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high risk disease

(2018) Susan Branford et al.   BLOOD

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer

(2017) Marilyn M. Li et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia

(2017) Mathilde Ruggiu et al.   LEUKEMIA & LYMPHOMA

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

(2017) Andreas Hochhaus et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of CML-blast crisis

(2016) Rüdiger Hehlmann et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

(2016) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

(2016) A Hochhaus et al.   LEUKEMIA

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

(2015) Elias Jabbour et al.   LANCET ONCOLOGY

Using Data Augmentation to Facilitate Conduct of Phase I–II Clinical Trials With Delayed Outcomes

(2014) Ick Hoon Jin et al.   JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia

(2013) Paolo Strati et al.   CANCER

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

(2012) Jorge E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis

(2011) H J Khoury et al.   BONE MARROW TRANSPLANTATION

Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation

(2011) D. Milojkovic et al.   HAEMATOLOGICA

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV

(2009) S. Saussele et al.   BLOOD

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

(2009) Thomas O'Hare et al.   CANCER CELL